The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world — including Fred Hutchinson Cancer Research Center, whose scientists will be presenting their research at the 2022 meeting.
The theme of the 2022 AACR annual meeting is: Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes.
The Rona Jaffe Foundation Endowed Chair Holder
AACR members have elected Greenberg as the AACR president-elect for 2022-2023. He will officially become president-elect on Monday, April 11, 2022, during the AACR’s Business Meeting of Members, and will assume the presidency in April 2023 at the next AACR Annual Meeting in Orlando, Florida.
Read more on Fred Hutch News: Dr. Phil Greenberg becomes president-elect of American Association for Cancer Research
Paul Stephanus Memorial Endowed Chair Holder
Opening Ceremony
April 10, 7:45-9:45 a.m.
Galloway will be inducted into the 2022 class of Fellows of the AACR Academy during the annual meeting’s opening ceremony. An expert on the connections between viruses and cancer, Galloway joins 255 scientists who have made significant and enduring impacts in cancer research and serve as a global brain trust of top contributors to cancer science and medicine.
Read more on Fred Hutch News: Dr. Denise Galloway elected Fellow of the American Association for Cancer Research Academy
Highlights of Presentations at AACR | More Fred Hutch Presentations at AACR
Oral presentation: A human paralog genetic interaction map with implications for cancer therapy and tumor evolution
Session: Dharma Master Jiantai Symposium in Targeted Therapy: Novel Genetic Screening Strategies to Identify Therapeutic Targets in Cancer
Presenter: Alice Berger, Ph.D., Innovators Network Endowed Chair holder
Monday, April 11, 10:16 a.m.
Berger will describe a new approach that allows scientists to knock out genes in tandem, which could help identify which gene pairs may play a role in cancer, and which could make for attractive therapeutic targets. Cancer cells exploit gene twins’ overlapping activities, relying on one gene twin to keep key cellular processes going after the first is lost. Researchers studying genes one at a time may miss a gene’s effects on cancer, not suspecting that its twin is pulling the strings in the background. It might lead them to dismiss a key cancer gene (and its therapeutic potential) — a misstep that Berger and her team hope their approach can help scientists avoid.
Related poster: Expanding cancer therapy options by leveraging synthetic lethal interactions between druggable paralogs
Session: Cancer Genomics 4
Presenter: Phoebe Parrish
April 12, 9-12:30 p.m.
Read more on Fred Hutch News: Could gene twins team up against cancer?
Oral presentation: Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer
Session: Minisymposium in Adoptive Cell Therapy
Presenter: Kristin Anderson, Ph.D.
Tuesday, April 12, 4:05 p.m.
Mesothelin, or MSLN, is a candidate immunotherapy target that contributes to invasive progression and malignancy in ovarian cancer. Anderson, a research associate at Fred Hutch, will describe preclinical experiments which demonstrate that combining engineered MSLN-specific T cells with three antibodies for checkpoint blockade — anti-PD-1, anti-Tim-3 and anti-Lag-3 — results in improved production of tumor-killing cytokines by the T cells and longer survival, compared to the use of the T cells alone or with only one or two antibodies for checkpoint blockade. Because many solid tumors overexpress these immune checkpoints and MSLN, this multi-checkpoint blockade strategy with engineered T cells may have the ability to enhance the efficacy of engineered adoptive T-cell therapy against other cancers.
Oral presentation: Effective multitargeted kinase inhibitors for metastatic castration-resistant prostate cancer predicted by integrative systems-based modeling
Session: Tyrosine Kinase and Phosphatase Inhibitors
Presenter: Eleonora Dondossola, Ph.D. (MD Anderson Cancer Center)
Tuesday, April 12, 1:30-5:00 p.m.
Using machine learning, deep neural networks and other artificial intelligence tools, Fred Hutch researchers in the labs of Drs. Taranjit Gujral and Peter Nelson and their collaborators identified inhibitors that block several kinases involved in prostate cancer growth and progression but aren’t likely to cause widespread side effects. The researchers’ preclinical testing suggests that combining multi-targeted kinase inhibitors with chemotherapy may represent an effective strategy for treating people with this cancer.
Read more on Fred Hutch News: Using AI to identify potential COVID-19, cancer therapies
Online-only poster: Cook and Move for Your Life: A pilot study of an online intervention to improve diet and physical activity among breast cancersurvivors
Session: Phase I Clinical Trials
Presenter: Heather Greenlee, N.D., Ph.D., MPH
April 8, 12-1 p.m.
Online-only poster: User characteristics of “Cook For Your Life” - a website designed to support cancer patients and survivors
Session: Population Sciences
Presenter: Heather Greenlee, N.D., Ph.D., MPH
April 8, 12-1 p.m.
Online-only poster: Predictors of objectively-measured sedentary time during the COVID-19 pandemic among breast cancer survivors participating in a diet and physical activity intervention
Session: Population Sciences
Presenter: Heather Greenlee, N.D., Ph.D., MPH
April 8, 12-1 p.m.
Online-only poster: Cardiovascular disease risk associated with breast cancer chemotherapy drugs: The Pathways Heart Study
Session: Drug Discovery
Presenter: Hanjie Shen, M.S.
April 8, 12-1 p.m.
Poster: Outcomes of an expanded access program for patients with gastrointestinal stromal tumors in low- and middle-income countries
Session: Clinical Research in Special Populations / Supportive Care and Survivorship Research
Presenter: Edward Briercheck , M.D., Ph.D.
April 10, 1:30-5 p.m.
Online-only poster: The ABID (Assessing the gut microbiota and Individual Diet) Study in the Navajo Nation
Sesson: Population Sciences
Presenter: Dornell Pete
April 8, 12-1 p.m.
Poster: Will novel systemic treatments alter the benefit of lung cancer screening?: A microsimulation study
Session: Descriptive Epidemiology Covering Cancer Incidence, Mortality, Clusters, and Trends
Presenter: Kemal Caglar Gogebakan, Ph.D.
April 10, 1:30-5 p.m.
Oral educational presentation: The function of immune cells in residual disease and cancer recurrence
Session: Cancer Dormancy and Immune Regulation
Presenter: James Alvarez, Ph.D.
April 8, 3:30-3:50 p.m.
Poster: CD8 T cells display distinct trajectories of T cell exhaustion in the bone marrow of mice with multiple myeloma
Session: Molecular Signaling and Metabolic and Epigenetic Regulation in Adaptive Tumor Immunity
Presenter: Simone Minnie, Ph.D.
April 11, 9-12:30 p.m.
Poster: Cellular profiling of leukapheresis and infusion products of patients enrolled in CD19 CAR T cell therapy identifies biomarkers associated with clinical outcomes
Session: Proteomics, Signaling Networks, and Biomarker Discovery
Presenter: Tony Chour
April 13, 9 a.m.-12:30 p.m.
Late-breaking poster: Duplex Sequencing reveals ubiquitous clonal hematopoiesis and complex donor-recipient clonal dynamics following HSCT
Session: Late-Breaking Research: Tumor Biology 2
Presenter: Jake Higgins, Ph.D.
April 11, 9-12:30 p.m.
Poster: Therapeutic targeting of CBFA2T3-GLIS2 infant AML with ELU001 - folate receptor alpha-directed C’Dot-drug-conjugate
Session: Drug Conjugates / Bispecific Antibodies
Presenter: Soheil Meshinchi, M.D.
April 11, 9-12:30 p.m.
Poster: UBTF tandem duplications (UBTF-TD) in childhood AML: Enrichment in FLT3-ITD and association with clinical outcome
Session: Translational Research: Molecular and Clinical
Presenter: Leila Robinson
April 12, 1:30-5 p.m.
Poster: Identification of USP9X as a novel regulator of RIT1 protein abundance and as a potential therapeutic target in RIT1-driven lung cancer
Session: GTPase and Ubiquitin Signaling
Presenter: Amanda Riley
April 12, 1:30-5 p.m.
An mRNA vaccine boost may help CAR T-therapy treat solid cancers
STAT | April 10, 2022
Dr. Anderson on overcoming suppressive signals by engineering T-cells in ovarian cancer
OncLive | April 12, 2022
Trying not one, but a three-drug combination to help engineered T-cells fight cancer
STAT | April 13, 2022
For more information or to arrange an interview, please email or call our media relations team.